Mogrify secures £830k in Phase II grant funding from SBRI Healthcare for cartilage therapy assessment.
The Phase II grant from SBRI Healthcare will fund pre-clinical safety and efficacy studies for regenerative cartilage treatments.
£830KGrant
Mogrify is a biopharmaceutical company developing in vivo reprogramming therapies to address degenerative conditions. Its proprietary platforms use big data and genomics to control human cell fate.
Mogrify has secured £830k in Phase II grant funding from SBRI Healthcare to support the pre-clinical assessment of its regenerative cartilage therapy. The capital will enable the company to advance its cell conversions toward clinical trials for conditions including osteoarthritis and cartilage defects. This financing follows previous Phase I backing received in April 2019.
From the founder
"We select projects strategically based on both commercial and scientific considerations and are delighted with the progress of this collaboration with Dr. Wael Kafienah’s laboratory at the University of Bristol. The continued support for our lead musculoskeletal asset from SBRI Healthcare has not only allowed us to reach this phase but will enable us to carry the chondrocyte conversions through to the next stage."
Karin Schmitt
CBO at Mogrify
Use of funds
- 01Fund research and development
